NMAD logo

NOMAD POWER SOLUTIONS INC

NMADNASDAQ
πŸ† #4357 by market capUS Equity
$3.79β–² $0.23 (+6.17%)
Market closed Β· at close
πŸ””
Track NMAD
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 6.2%
7dβ–² 7.7%
14dβ–² 8.5%
30dβ–Ό 9.3%
ytdβ–Ό 3.4%
1yβ–Ό 22.0%
🏦Market Cap
$72M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
88
Very Good

Trading Snapshot

Day Range
$3.75 – $3.82
52-Week Range
$3.12 – $7.70
Volume
$2.00B
Avg Volume
$1.35B
Shares Outstanding
19.0M
Next Earnings
Nov 13, 2026

Fundamentals Snapshot

Annual Revenue
$22M
Last Q Revenue
$5M
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-0.98
Dividend Yield
β€”

Why Investors Own NMAD

  • βœ“High-growth profile β€” revenue up +53.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 79% gross margin and 16% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NMAD logo

NOMAD POWER SOLUTIONS INC

NMAD
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$22Mβ–² +54.7% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.8%β–² +2.8% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$3Mβ–² +54.7% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$4Mβ–² +54.7% YoY
StockOtter Β· stockotter.space

About NOMAD POWER SOLUTIONS INC

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
88/100

Analyst Price Target

β“˜
Average Target
$4.94
β–² +30.4% Upside
High Target$5.37
Low Target$3.88
Based on 18 analysts

Latest News & Updates